|
1
|
Logan RM: 1st World Congress of the
International academy of oral oncology: Oral cancer-a global
challenge. Expert Rev Anticancer Ther. 7:975–976. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kulkarni P and Saxena U: Head and neck
cancers, the neglected malignancies: Present and future treatment
strategies. Expert Opin Ther Targets. 18:351–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Quan J, Johnson NW, Zhou G, Parsons PG,
Boyle GM and Gao J: Potential molecular targets for inhibiting bone
invasion by oral squamous cell carcinoma: A review of mechanisms.
Cancer Metastasis Rev. 31:209–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warnakulasuriya S, Johnson NW and van der
Waal I: Nomenclature and classification of potentially malignant
disorders of the oral mucosa. J Oral Pathol Med. 36:575–580. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sarode SC, Sarode GS and Tupkari JV: Oral
potentially malignant disorders: Precising the definition. Oral
Oncol. 48:759–760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van der Waal I: Potentially malignant
disorders of the oral and oropharyngeal mucosa; present concepts of
management. Oral Oncol. 46:423–425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mehrotra R and Gupta DK: Exciting new
advances in oral cancer diagnosis: Avenues to early detection. Head
Neck Oncol. 3:332011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barclay AN and Van den Berg TK: The
interaction between signal regulatory protein alpha (SIRPα) and
CD47: Structure, function, and therapeutic target. Annu Rev
Immunol. 32:25–50. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jaiswal S, Chao MP, Majeti R and Weissman
IL: Macrophages as mediators of tumor immunosurveillance. Trends
Immunol. 31:212–219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takizawa H and Manz MG: Macrophage
tolerance: CD47-SIRP-alpha-mediated signals matter. Nat Immunol.
8:1287–1289. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Willingham SB, Volkmer JP, Gentles AJ,
Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin
R, Cohen JD, et al: The CD47-signal regulatory protein alpha
(SIRPa) interaction is a therapeutic target for human solid tumors.
Proc Natl Acad Sci USA. 109:6662–6667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki S, Yokobori T, Tanaka N, Sakai M,
Sano A, Inose T, Sohda M, Nakajima M, Miyazaki T, Kato H and Kuwano
H: CD47 expression regulated by the miR-133a tumor suppressor is a
novel prognostic marker in esophageal squamous cell carcinoma.
Oncol Rep. 28:465–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chao MP, Weissman IL and Majeti R: The
CD47-SIRPα pathway in cancer immune evasion and potential
therapeutic implications. Curr Opin Immunol. 24:225–232. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao XW, van Beek EM, Schornagel K, Van
der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M,
Matozaki T, Kraal G, et al: CD47-signal regulatory protein-α
(SIRPα) interactions form a barrier for antibody-mediated tumor
cell destruction. Proc Natl Acad Sci USA. 108:18342–18347. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chao MP, Alizadeh AA, Tang C, Jan M,
Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL and Majeti R:
Therapeutic antibody targeting of CD47 eliminates human acute
lymphoblastic leukemia. Cancer Res. 71:1374–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chao MP, Alizadeh AA, Tang C, Myklebust
JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al:
Anti-CD47 antibody synergizes with rituximab to promote
phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142:699–713.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chan KS, Espinosa I, Chao M, Wong D,
Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, et
al: Identification, molecular characterization, clinical prognosis,
and therapeutic targeting of human bladder tumor-initiating cells.
Proc Natl Acad Sci USA. 106:14016–14021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Warnakulasuriya S, Reibel J, Bouquot J and
Dabelsteen E: Oral epithelial dysplasia classification systems:
Predictive value, utility, weaknesses and scope for improvement. J
Oral Pathol Med. 37:127–133. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lascorz J, Bevier M, Schönfels V W,
Kalthoff H, Aselmann H, Beckmann J, Egberts J, Buch S, Becker T,
Schreiber S, et al: Association study identifying polymorphisms in
CD47 and other extracellular matrix pathway genes as putative
prognostic markers for colorectal cancer. Int J Colorectal Dis.
28:173–181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Majeti R, Chao MP, Alizadeh AA, Pang WW,
Jaiswal S, Gibbs KD Jr, van Rooijen N and Weissman IL: CD47 is an
adverse prognostic factor and therapeutic antibody target on human
acute myeloid leukemia stem cells. Cell. 138:286–299. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jaiswal S, Jamieson CH, Pang WW, Park CY,
Chao MP, Majeti R, Traver D, van Rooijen N and Weissman IL: CD47 is
upregulated on circulating hematopoietic stem cells and leukemia
cells to avoid phagocytosis. Cell. 138:271–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edris B, Weiskopf K, Volkmer AK, Volkmer
JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB,
Fletcher JA, et al: Antibody therapy targeting the CD47 protein is
effective in a model of aggressive metastatic leiomyosarcoma. Proc
Natl Acad Sci USA. 109:6656–6661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu G, He Y, Yang S, Chen B, Zhou M and Xu
XJ: Identification of Gene and MicroRNA signatures for oral cancer
developed from oral leukoplakia. Biomed Res Int. 2015:8419562015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim MJ, Lee JC, Lee JJ, Kim S, Lee SG,
Park SW, Sung MW and Heo DS: Association of CD47 with natural
killer cell-mediated cytotoxicity of head-and-neck squamous cell
carcinoma lines. Tumour Biol. 29:28–34. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chao MP, Tang C, Pachynski RK, Chin R,
Majeti R and Weissman IL: Extranodal dissemination of non-Hodgkin
lymphoma requires CD47 and is inhibited by anti-CD47 antibody
therapy. Blood. 118:4890–4901. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fortin G, Raymond M, Van VQ, Rubio M,
Gautier P, Sarfati M and Franchimont D: A role for CD47 in the
development of experimental colitis mediated by
SIRPalpha+CD103-dendritic cells. J Exp Med. 206:1995–2011. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baba N, Van VQ, Wakahara K, Rubio M,
Fortin G, Panzini B, Soucy G, Wassef R, Richard C, Tamaz R, et al:
CD47 fusion protein targets CD172a+ cells in Crohn's disease and
dampens the production of IL-1beta and TNF. J Exp Med.
210:1251–1263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soto-Pantoja DR, Terabe M, Ghosh A,
Ridnour LA, DeGraff WG, Wink DA, Berzofsky JA and Roberts DD: CD47
in the tumor microenvironment limits cooperation between antitumor
T-cell immunity and radiotherapy. Cancer Res. 74:6771–6783. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bian Z, Guo Y, Ha B, Zen K and Liu Y:
Regulation of the inflammatory response: Enhancing neutrophil
infiltration under chronic inflammatory conditions. J Immunol.
188:844–853. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tomizawa T, Kaneko Y, Kaneko Y, Saito Y,
Ohnishi H, Okajo J, Okuzawa C, Ishikawa-Sekigami T, Murata Y,
Okazawa H, et al: Resistance to experimental autoimmune
encephalomyelitis and impaired T cell priming by dendritic cells in
Src homology 2 domain-containing protein tyrosine phosphatase
substrate-1 mutant mice. J Immunol. 179:869–877. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Anderson A and Ishak N: Marked variation
in malignant transformation rates of oral leukoplakia. Evid Based
Dent. 16:102–103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Öhman J, Mowjood R, Larsson L, Kovacs A,
Magnusson B, Kjeller G, Jontell M and Hasseus B: Presence of
CD3-positive T-cells in oral premalignant leukoplakia indicates
prevention of cancer transformation. Anticancer Res. 35:311–317.
2015.PubMed/NCBI
|
|
33
|
Murata Y, Kotani T, Ohnishi H and Matozaki
T: The CD47-SIRPα signalling system: Its physiological roles and
therapeutic application. J Biochem. 155:335–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
